

Nilandron® (nilutamide) – First-Time Generic

- On July 18, 2016, <u>Ani Pharmaceuticals launched</u> an <u>AB-rated</u> generic version of Concordia's <u>Nilandron</u> (<u>nilutamide</u>) 150 mg oral tablets.
- Nilandron is indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D₂).
 - For maximum benefit, Nilandron treatment must begin on the same day as or on the day after surgical castration.
- According to IMS Health, the U.S. annual sales of Nilandron were approximately \$23 million for the last 12 months.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.